BARTEK-INGREDIENTS
25.1.2023 21:05:42 CET | Business Wire | Press release
Bartek Ingredients advances its plans to strengthen its position as the world’s largest producer of malic and food-grade fumaric acid with the groundbreaking of its state-of-the-art, $175 million malic and fumaric acid production facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005653/en/
Left to right: Tim Larson (Bartek), Minister Neil Lumsden, MP Chad Collins, Minister Lisa Thompson, Hamid Goli (Bartek), Jose Kafie (Bartek), John Burrows (Bartek), Jim Vincent (Bartek), Steven Chambers (Bartek), Minister Vic Fedeli. (Photo: Business Wire)
The company held a groundbreaking ceremony on Jan. 12 with Canadian government officials and local community leaders to celebrate the official commencement of the construction project.
“We are thrilled to be breaking ground on our new facility which will set a new global benchmark for safety, efficiency, and environmental performance,” Bartek President and CEO John Burrows said. “We are pleased to be investing in the community of Stoney Creek and proud to play an integral part in supporting local industries and the local economy. We are thankful for our partnerships with the provincial and federal government and Environment Hamilton and their support and guidance throughout the process.”
Among those in attendance at the groundbreaking were Neil Lumsden, Minister of Tourism, Culture and Sport and Member of Provincial Parliament for Hamilton East, Victor Fedeli, Minister of Economic Development and Trade, Lisa Thompson, Minister of Agriculture, Food and Rural Affairs, and Chad Collins, Member of Federal Parliament for Hamilton East-Stoney Creek.
“Congratulations to everyone at Bartek Ingredients on this exciting milestone,” Minister Fedeli said. “Bartek’s $175 million investment will ensure that the company can continue to expand and create more good-paying jobs in Hamilton and the surrounding region. Together, we’re building a stronger Ontario with opportunities for all people.”
The facility will double Bartek’s production capacity and propel new product development and other innovation efforts. It is also being built with sustainability in mind and is expected to be the most environmentally sustainable facility in the industry – projected to reduce per unit greenhouse gas emissions by more than 80 percent.
“Ontario has a clean energy advantage and is a sustainable and predictable place to do business,” Minister Piccini said. “As a result, we’re attracting the jobs of tomorrow. My Ministry was proud to work closely with Bartek through the permitting and approvals process to help secure this significant investment to Ontario.”
Minister Thompson added: “Bartek’s new state-of-the-art facility will be a shining example of Ontario’s robust agri-food manufacturing and processing sector. This major investment will create good-paying jobs in the local community and further strengthen Ontario’s value-added food supply chain.”
Through this project, Bartek will inject $100 million into the local Stoney Creek economy. The facility is expected to be fully operational at the beginning of 2024.
“Hamilton’s Bartek facility will soon become one of the world’s largest malic and food-grade acid production plants,” Minister Lumsden said. “Our government is excited to see local manufacturers, such as Bartek, invest in Ontario to grow and create more good-paying jobs right here in Hamilton!”
For more information, please visit bartek.ca or contact Bartek at info@bartek.ca.
About Bartek Ingredients
For over 50 years, Bartek Ingredients Inc. has been a leading global manufacturer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. With new ownership in 2019 and significant investments, Bartek’s presence in the food and beverage space continues to be bolstered by highly innovative products and services that utilize deep product expertise and application knowledge to offer solutions to industry needs. For more information about Bartek, visit bartek.ca/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005653/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
